ZIVO Bioscience, Inc.

OTCPK:ZIVO Stock Report

Market Cap: US$20.8m

ZIVO Bioscience Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

OTCPK:ZIVO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Apr 26BuyUS$200,000Mark StromeIndividual100,000US$2.00
27 Feb 26BuyUS$14,998HEP Investments, LLCCompany1,543US$9.72
12 Feb 26BuyUS$195,400Strome Investment Management, L.P.Company20,000US$9.77
10 Feb 26BuyUS$24,997HEP Investments, LLCCompany2,434US$10.27
26 Jan 26BuyUS$99,995John PayneIndividual11,709US$8.54
26 Jan 26BuyUS$99,995Alison CornellIndividual11,709US$8.54
14 Jan 26BuyUS$14,993Christopher MaggioreIndividual1,766US$8.49
14 Jan 26BuyUS$14,993HEP Investments, LLCCompany1,766US$8.49
28 Nov 25BuyUS$24,993HEP Investments, LLCCompany2,777US$9.00
13 Oct 25BuyUS$249,996Strome Investment Management, L.P.Company20,259US$12.34
10 Oct 25BuyUS$19,991HEP Investments, LLCCompany1,659US$12.05
08 Oct 25BuyUS$284,421Christopher MaggioreIndividual23,682US$12.01
30 Sep 25BuyUS$244,999HEP Investments, LLCCompany15,322US$15.99

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of ZIVO?
Owner TypeNumber of SharesOwnership Percentage
Institutions4,4640.108%
Hedge Funds472,94211.4%
VC/PE Firms583,61514.1%
Individual Insiders1,522,23736.7%
General Public1,568,34937.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 9 shareholders own 62.22% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.1%
HEP Investments, LLC
583,615US$2.9m0.99%no data
13.8%
Mark Strome
572,942US$2.9m0%no data
12.5%
Christopher Maggiore
519,292US$2.6m0.34%no data
11.4%
Strome Investment Management, L.P.
472,942US$2.4m4.42%56.52%
6.73%
Alison Cornell
279,481US$1.4m4.37%no data
3.15%
Nola Masterson
130,904US$654.5k0%no data
0.47%
John Payne
19,618US$98.1k148%no data
0.11%
CoreCap Advisors, LLC
4,360US$21.8k0%no data
0.0025%
The Huntington Trust Company, National Association
104US$521.00%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/25 13:40
End of Day Share Price 2026/07/23 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ZIVO Bioscience, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group